Here is one of metabolism's strangest contradictions: the body can carry an enormous reserve of stored energy and still behave as though it needs more. You can gain weight while feeling tired. Cravings can become more insistent when the last thing you appear to need is additional fuel.

That experience is usually framed as a battle between appetite and willpower. Semaglutide has helped prove that this framing is incomplete. By changing GLP-1 signaling, it can change appetite, reduce food intake, and substantially alter a person's weight trajectory. Biology—not simply discipline—matters.

But what if appetite is only one side of the problem? What if metabolism also contains a fuel-conservation program—one that helps explain why hunger, fatigue, and fat storage can rise together?

This is where fructose enters the story. Fructose is not merely another source of calories. Its metabolism can consume cellular ATP, temporarily capture phosphate, generate uric acid, and activate programs that favor conservation and storage.[5] LIV3's hypothesis is that repeated activation of this pathway may help create a body that is storing energy while some of its cells behave as though energy is scarce.

And this is why luteolin belongs in the same conversation as semaglutide. Its relevance is not that it mimics a GLP-1 medicine. It is that laboratory research found luteolin can inhibit ketohexokinase, also called fructokinase, the enzyme at the entrance to fructose metabolism.[9]

One approach has already produced major clinical outcomes. The other points toward a distinct, earlier research question. Comparing them lets us ask something more useful than which one “wins”: Are appetite control and cellular fuel regulation two layers of the same metabolic problem?

Why would a well-fed body act short of energy?

Weight gain still requires energy to be stored, and reducing intake can be a powerful lever. But why does the body defend stored energy so aggressively? Why can cravings and fatigue persist when abundant energy is already available?

The Fructose Model starts with the idea that sugar is more than a collection of calories: it is also an elegant fuel-management system. Glucose is widely used as fuel. In some contexts, fructose metabolism may help shift fuel handling toward conservation and storage. Dose, food source, energy surplus, tissue, and recovery matter. A response that helped when food periodically disappeared may become maladaptive when abundance is continuous.

This does not make fructose the sole cause of obesity or metabolic dysfunction. Sleep, activity, genetics, medications, hormones, food environment, muscle mass, stress, and many other factors matter. The hypothesis is that fructose metabolism may be a central and underappreciated coordinator within that larger system.

How does semaglutide change appetite and weight?

Semaglutide is a GLP-1 receptor agonist. GLP-1 signaling affects appetite, food intake, insulin and glucagon responses, and gastric emptying. In the United States, Wegovy has weight-management indications for defined populations; Ozempic contains the same active drug but has different labeled indications.[1]

The clinical evidence is substantial. In the 68-week STEP 1 trial, adults with overweight or obesity but without diabetes lost an average of 14.9% of body weight with weekly semaglutide 2.4 mg, compared with 2.4% with placebo, alongside lifestyle intervention.[2] In the SELECT trial, semaglutide also reduced major cardiovascular events in a specific high-risk population with established cardiovascular disease and overweight or obesity.[3]

A 60-week randomized trial published in 2026 helps clarify the weight-loss effect. Participants assigned to semaglutide ate less during laboratory meals at weeks 20, 40, and 60; at week 60, the difference was about 270 calories at lunch. Several subjective appetite measures no longer differed significantly by weeks 40 or 60, even though measured intake remained lower.[4]

Semaglutide does more than demand willpower: it changes biological signaling in ways that help people eat less, with clinical outcomes that cannot be dismissed as cosmetic.

At the same time, its clearest weight-management lever is still a reduction in energy intake. The fructose hypothesis asks a different question: What determines the metabolic instructions attached to the fuel already entering—or being produced within—the body?

The useful comparison is not natural versus pharmaceutical. It is a comparison between layers:

The evidence is not equal. The comparison is about where each idea enters the system.

Semaglutide and luteolin enter the metabolic conversation at different points—and with very different evidence maturity.

How is fructose metabolism different?

Glucose and fructose contain the same number of calories per gram, but cells do not initially process them in the same way.

When fructose enters its principal metabolic pathway, ketohexokinase uses ATP to attach a phosphate and create fructose-1-phosphate. ATP is often called the cell's energy currency, but it also helps a cell sense whether energy is abundant or scarce.

Ketohexokinase can act quickly. When fructose arrives rapidly enough, phosphate becomes temporarily captured in fructose-1-phosphate and ATP levels fall. AMP is then broken down through the purine-degradation pathway, producing uric acid. This sequence—rapid phosphorylation, phosphate sequestration, ATP depletion, and uric-acid generation—is established biochemistry.[5]

Fructose metabolism can also promote de novo lipogenesis, reduce fat oxidation, influence mitochondrial oxidative stress, and activate nutrient-sensing programs that favor storage. A 2026 review in Nature Metabolism interprets fructose as an ancient signal of abundance that can help direct carbohydrate toward storage.[5]

Human challenge studies show that large acute fructose loads can change liver phosphate metabolites and ATP. The pattern is not always a simple deeper-depletion story: in a 2026 study, participants with metabolic dysfunction-associated steatotic liver disease had a blunted acute phosphate-and-ATP response compared with participants without the condition.[13] Depletion and recovery may matter more than a one-directional assumption.

This is what I mean by a fuel regulator: fructose adds energy, but its metabolism can also help change what the system does with energy.

The body can also make fructose

Diet is not the only route into this pathway. Through the polyol pathway, glucose can be converted first into sorbitol and then into fructose. Endogenous fructose production has been documented in human tissues. During an experimental hyperglycemic clamp in eight adults, brain fructose rose alongside brain glucose, consistent with local fructose production through the polyol pathway.[14]

Endogenous fructose is real. The unanswered question is how much it contributes to common metabolic problems in different people and circumstances. Animal and tissue studies suggest that high glucose, high salt, dehydration, ischemia, and oxidative stress can activate the pathway; its quantitative importance in everyday human disease needs more direct measurement.[6]

That distinction matters. Reducing dietary fructose exposure may be useful, but diet alone may not fully describe the pathway if the body can also manufacture fructose from other inputs.

The low-energy-cell hypothesis

Here is where established pathway biology becomes a broader LIV3 hypothesis.

LIV3 hypothesizes that if fructose metabolism is repeated faster than vulnerable cells can recover, some cells may begin behaving as though usable energy is scarce even while the body has abundant energy stored elsewhere. In this model, insulin resistance could sometimes act partly as a protective adaptation—a way of limiting additional fuel pressure when the machinery for handling that fuel is already strained.

If the model is correct, it predicts connections among experiences that otherwise seem contradictory:

• stored energy can rise while subjective energy remains poor;
• cravings can coexist with weight gain;
• eating less can reduce incoming fuel without immediately resolving the cellular signals that encouraged conservation;
• inflammation, oxidative stress, and impaired metabolic flexibility can reinforce one another.

Whether fructose-driven ATP changes cause cravings, fatigue, or insulin resistance in humans remains a testable prediction, not an established explanation for every person. The model offers a way to investigate why intake, storage, and usable cellular energy do not always move together.

The hypothesis also changes the scientific comparison with semaglutide. Semaglutide can reduce the amount of energy entering the system. Fructose-pathway research asks whether part of the machinery that assigns metabolic meaning to that energy can also be measured and altered. These are distinct biological questions—and they are not inherently contradictory.

Why does ketohexokinase matter?

Ketohexokinase is the first committed step in fructose metabolism. If the pathway matters, inhibiting this enzyme should produce measurable changes. That prediction has moved beyond theory.

In a small randomized phase 2a study, the selective KHK inhibitor PF-06835919 reduced whole-liver fat relative to placebo after six weeks in adults with nonalcoholic fatty liver disease and changed inflammatory markers.[7] The study was short and tested a pharmaceutical inhibitor—not luteolin—but it showed that KHK is a biologically active human intervention point.

A second phase 2a study tested the molecule for 16 weeks in adults with fatty liver disease and type 2 diabetes. The higher dose again reduced MRI-measured liver fat relative to placebo, while the HbA1c change was not statistically significant.[12] KHK inhibition did something measurable, but it did not correct every metabolic marker.

A first-in-human study of LY3522348 found dose-dependent biomarker changes after a fructose beverage that were consistent with inhibition of fructose metabolism.[8] It measured target engagement, not clinical benefit. Together, these studies show that the pathway can be engaged and measured in people.

The question is therefore which interventions can alter fructose metabolism safely, at what dose, in which tissues, and with what clinical consequences.

What evidence connects luteolin to ketohexokinase?

Luteolin is a flavonoid found in a variety of plants. It has attracted research interest because it interacts with numerous biological pathways, including inflammatory and oxidative-stress signaling. For LIV3, its most intriguing feature is more specific: in a 2017 study, luteolin inhibited fructokinase in an enzyme assay and in human proximal-tubule cells. The researchers also used intravenous luteolin in a mouse model of acute kidney injury and reported improved kidney-injury measures.[9]

That study established a serious research lead. It did not establish that oral luteolin inhibits KHK in humans or causes human weight loss. The route was different, the animal model was acute kidney injury rather than obesity, and luteolin has other molecular targets that could have contributed to the result.

The right conclusion is not that luteolin has failed. It is that the decisive experiment has not yet been done.

Laboratory findings make luteolin a research lead; oral KHK target engagement and clinical outcomes still need direct human study.

What human evidence exists around luteolin?

Evidence stays with what researchers actually studied:

• Isolated luteolin: A 40-person randomized obesity study was registered in Japan. The registry says recruitment ended and the data were considered complete in May 2020, but results remain unpublished. A silent result cannot be treated as either proof or disproof.[10]
• Altilix: A six-month randomized trial reported modest weight and metabolic changes for Altilix, a multi-constituent artichoke-leaf extract containing chlorogenic acids and luteolin derivatives. The study cannot tell us that luteolin caused the findings.[11]
• Experimental KHK inhibitors: PF-06835919 and LY3522348 are purpose-built pharmaceutical molecules. Their human findings help validate KHK as a measurable target, but they are not luteolin evidence.
• SugarShield: SugarShield is a different finished formulation. Results from isolated luteolin, Altilix, or experimental KHK drugs do not become SugarShield outcomes.

These distinctions are how a plausible mechanism becomes reliable human evidence.

What would a decisive human luteolin study need to show?

A useful human study would need to answer several linked questions:

1. Does the chosen oral formulation produce adequate luteolin exposure?
2. Does it measurably engage the KHK/fructose pathway in people?
3. Do changes in pathway biomarkers correspond with changes in cravings, energy, liver fat, insulin sensitivity, or other prespecified outcomes?
4. Are any benefits clinically meaningful and durable?
5. Which effects, if any, are actually attributable to KHK modulation rather than luteolin's other actions?

It is a demanding—but testable—research program.

Can the mechanisms coexist—and what has not been tested?

GLP-1 signaling and fructose metabolism are different biological layers; evidence for one does not make the other irrelevant. Different mechanisms do not establish that two interventions are complementary. No clinical evidence identified here shows that luteolin or SugarShield adds benefit to semaglutide, is compatible with it, permits a lower dose, or assists discontinuation.

A future combination study could define the oral luteolin formulation, measure exposure and KHK target engagement, monitor interactions, and test whether adding it changes a prespecified outcome beyond semaglutide alone. Until then, coexistence of the biological ideas is not evidence about combined treatment.

Anyone using semaglutide or another prescription medicine should discuss supplements and medication changes with a physician or pharmacist.

Why this matters to LIV3

SugarShield contains luteolin and was designed around the fructose-metabolism hypothesis described here. That is a reason to follow the science closely, not evidence that the finished product reproduces an experimental KHK drug or produces semaglutide-like weight loss.

SugarShield is not a treatment for obesity, diabetes, fatty liver disease, or any other disease. The current evidence does not establish it as a substitute for semaglutide. Its relevance to this conversation is that LIV3 is pursuing a different metabolic layer—one centered on how fructose is processed and how that processing may influence cellular energy regulation.

The responsible next step is direct human validation of the formulation, target engagement, and outcomes.

A more complete model of metabolic health

Semaglutide proved that changing appetite biology can change weight and health outcomes. The growing KHK literature identifies fructose metabolism as another measurable target—one tied to ATP, phosphate, uric acid, fat production, and cellular fuel selection. Laboratory work makes luteolin an intriguing lead at that doorway.

The evidence is not symmetrical. The ideas do not need to be.

One approach already has strong clinical evidence. The other asks whether a natural compound can help interrogate an underappreciated metabolic mechanism. The hypothesis is that appetite signals and intracellular fuel handling are both worth studying. If the model is right, the future will not belong to a winner in a luteolin-versus-semaglutide contest. It will belong to a more complete understanding of metabolism.

Commercial-interest disclosure: LIV3 Health publishes this article and makes SugarShield, a formulation containing luteolin. The ingredient and pathway research discussed here did not test SugarShield for weight loss or use with semaglutide.

This article explains research and is not medical advice. Do not start a supplement, combine it with semaglutide, change a dose, or stop prescribed treatment on the basis of this article; discuss those decisions with a clinician or pharmacist who knows your health history and medications.

Photography: cottonbro studio and Polina Tankilevitch / Pexels.

References

1. U.S. Food and Drug Administration. Wegovy prescribing information and Ozempic prescribing information.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward. 2026.
5. Johnson RJ, et al. Fructose: Metabolic Signal and Modern Hazard. Nature Metabolism. 2026.
6. Lanaspa MA, et al. Endogenous fructose production: what do we know and how relevant is it?. Current Opinion in Clinical Nutrition and Metabolic Care. 2019.
7. Kazierad DJ, et al. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers. Med. 2021;2(7):800–813.e3. DOI 10.1016/j.medj.2021.04.007.
8. MacKrell J, et al. LY3522348, a New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults. 2025.
9. Andres-Hernando A, et al. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice. Nature Communications. 2017.
10. University Hospital Medical Information Network. Effect of luteolin on obesity, UMIN000034570.
11. Castellino G, et al. A standardized polyphenol-rich extract from Cynara scolymus in adults with metabolic syndrome. Nutrients. 2019.
12. Saxena AR, et al. A phase 2a randomized trial of PF-06835919 in patients with NAFLD and type 2 diabetes. Diabetes, Obesity and Metabolism. 2023.
13. Bril F, et al. Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. Journal of Clinical Endocrinology & Metabolism. 2026.
14. Hwang JJ, et al. The human brain produces fructose from glucose. JCI Insight. 2017.